CRISPR Therapeutics (Nasdaq: CRSP), a leading biopharmaceutical company dedicated to pioneering transformative gene-based therapies for serious illnesses, has announced a strategic move in securing approximately $280 million through a registered…
CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company dedicated to pioneering gene-based treatments for severe illnesses, disclosed today that the European Commission has granted conditional marketing authorization for CASGEVY™ (exagamglogene autotemcel…
Results from the latest analyses of bimekizumab phase 3 trials in patients with moderate to severe hidradenitis suppurativa (HS) will be presented at the 13th Conference of the European Hidradenitis…
Today, Baxter, a prominent player in the global medtech arena, disclosed its financial outcomes for the fourth quarter and the entirety of 2023, concluding on December 31st. Additionally, the company…
Otsuka Pharmaceutical Co., Ltd. (Otsuka) announces that Novartis Pharma K.K. (Novartis Pharma) has received approval for an expanded treatment indication of pediatric chronic heart failure for Entresto® Tablets, an angiotensin…
Today’s announcement unveils Otsuka Foods’ plans to introduce five revamped Bon Curry NEO products, each boasting a richer flavor profile, all under the renowned Bon Curry brand. Set for release…
Otsuka Pharmaceutical Co., Ltd. (Otsuka) and Jolly Good Inc. (Jolly Good) have commenced the delivery of innovative content aimed at supporting families of individuals in Japan grappling with severe social…
BioNTech SE (Nasdaq: BNTX, “BioNTech”), a next-generation immunotherapy company pioneering novel therapies for cancer and other serious diseases, and Autolus Therapeutics plc (Nasdaq: AUTL, “Autolus”), a clinical-stage biopharmaceutical company developing next-generation programmed T…
At an upcoming presentation at the RSVVW’24 conference, Moderna will share follow-up data from its ongoing ConquerRSV Phase 3 study of its investigational RSV vaccine candidate, mRNA-1345. As previously published…
Takeda (TSE:4502/NYSE:TAK) has unveiled positive topline findings from a randomized, double-blind, placebo-controlled, multiple dose Phase 2b trial assessing TAK-861, an oral orexin receptor 2 (OX2R) agonist, in patients diagnosed with…
Chugai Pharmaceutical Co., Ltd. (TOKYO: 4519) has revealed that the anti-CD20/CD3 bispecific antibody mosunetuzumab has successfully met the primary endpoint of achieving a complete response rate (CRR) in an expansion…
Chugai Pharmaceutical Co., Ltd. (TOKYO: 4519) has announced today the approval of crovalimab (known as 派圣凯® in China), a humanized complement inhibitor C5 monoclonal antibody developed by Chugai, by the…